Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Publication Date

2023

Content Type

Article

PubMed ID:

36521103

Additional Authors:

Additional authors and institutional affiliations

This document is currently not available here.

Share

COinS